Table 2.
Disease Characteristics Between RA Individuals with and without Sarcopenia
| Indicators | RA without Sarcopenia (n=210) | RA with Sarcopenia (n=339) | Z /t /χ2 | P= |
|---|---|---|---|---|
| Age (years) | 54.04±11.29 | 58.67±12.90 | 5.697 | 0.0001 |
| Female (%) | 159 (75.7%) | 310/339 (91.5%) | 20.313 | 0.0001 |
| BMI (kg/m2) | 24.19±3.42 | 20.90±3.30 | 4.067 | 0.0001 |
| Disease Duration (years) | 7 (2–17.25) | 11 (4–20) | 2.683 | 0.005 |
| VAS (cm) | 5.09±1.94 | 5.31±2.00 | 1.247 | 0.213 |
| SJC | 6.0 (3.0–11.7) | 7.0 (4.0=12.0) | 0.888 | 0.374 |
| TJC | 9.5(5.25–16.0) | 12.0 (6.5–20.5) | 1.879 | 0.060 |
| Morning stiffness (min) | 0 (0–30) | 0 (0–10) | 2.380 | 0.812 |
| ESR (mm/h) | 54.50 (30.0–77.75) | 66 (46.50–88.50) | 3.252 | 0.001 |
| CRP (mg/l) | 21.48 (8.42–54.83) | 32.29 (14.22–62.89) | 2.399 | 0.016 |
| DAS28 | 5.02±1.21 | 5.29±1.20 | 2.753 | 0.006 |
| HAQ | 1.04±0.74 | 1.44±2.02 | 2.785 | 0.006 |
| RF (U/mL) | 99.10 (24.10–271.88) | 98.0 (26.70–254.5) | 1.801 | 0.072 |
| ACPA (RU/mL) | 284.5 (72–820.5) | 352.0 (99.5–964.5) | 1.930 | 0.054 |
| Sharp’score | 38 (10–77.25) | 74 (19.00–156.5) | 4.873 | 0.0001 |
| BMD-Neck (g/cm2) | 0.84±0.14 | 0.75±1.16 | 6.797 | 0.0001 |
| BMD-Hip (g/cm2) | 0.88±0.14 | 0.77±0.15 | 8.964 | 0.0001 |
| BMD-L1 (g/cm2) | 0.94±0.17 | 0.85±0.15 | 6.164 | 0.0001 |
| BMD-L2 (g/cm2) | 1.00±0.16 | 0.89±0.18 | 7.853 | 0.0001 |
| BMD-L3 (g/cm2) | 1.09±0.17 | 0.96±0.19 | 8.004 | 0.0001 |
| BMD-L4 (g/cm2) | 1.11±0.17 | 0.98±0.18 | 7.73 | 0.0001 |
| BMD-L1-4 (g/cm2) | 1.07±0.16 | 0.95±0.18 | 7.657 | 0.0001 |
| GCs user (%) | 107 (51.0%) | 209 (61.7%) | 5.790 | 0.017 |
| Does of GCs/D | 3.86±4.53 | 5.48±5.38 | 3.071 | 0.002 |
| DMARDs user (%) | 93 (44.3%) | 141 (41.6%) | 0.338 | 0.594 |
Abbreviations: BMI, body mass index; VAS, visual analog scale; SJC, swollen joint count; TJC, tender joint count; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; DAS28, disease activity score at 28 joints; HAQ, health assessment questionnaire; RF, rheumatoid factor; ACPA, anti-citrullinated peptide antibodies; BMD, bone mineral density; GCs, glucocorticoids; DMARDs, disease-modifying anti-arthritis drugs.